Skip to main content

Table 3 Comparison of patient characteristics between those with and without drug resistance

From: Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions

Characteristic Patients with TDR Patients without TDR OR (95% CI) p-value
Number (%) Number (%)
  N=19 N=136   
Country of Birth     
Canada 12 (63.2%) 79 (58.1%) 1.44 (0.47, 4.62) 0.48
Other 7 (36.8%) 57 (41.9%)
Gender     
Male 18 (94.7%) 97 (71.3%) 7.18 (1.06, 309.13) 0.03
Female 1 (5.3%) 39 (28.7%)
Mean age (range) 38 (23-49) 37 (18-70)   0.73
Exposure Category     
MSM 13 (68.4%) 48 (35.3%)   
IDU 1 (5.3%) 17 (12.5%)   
MSM/IDU 1 (5.3%) 1 (0.7%)   
HIV endemic 2 (10.5%) 32 (23.5%)   
Heterosexual 0 35 (25.7%)   
Other 0 1 (0.7%)   
Unknown 2 (10.5%) 2 (1.5%)   
MSM 13 (68.4%) 48 (35.3%) 3.97 (1.30, 12.63) 0.005
All other 6 (31.6%) 88 (64.7%)
Clade     
B 18(94.7%) 88 (64.7%) 9.73 (1.45,417.43) 0.009
Non-B 1 (5.3%) 48 (35.3%)
CD4 Count     
<200 6 (31.6%) 41 (30.1%)   0.97
200-500 8 (42.1%) 64 (47.1%)  
>500 5 (26.3%) 29 (21.3%)  
Unknown 0 2 (1.5%)  
Viral Load     
<5,000 5 (21.1%) 36 (27.2%)   0.37
5,000-10,000 3 (15.8%) 13 (9.6%)  
10,000-100,000 8 (47.4%) 57 (41.2%)  
>100,000 2 (10.5%) 29 (21.3%)  
Unknown 1 (5.3%) 1 (0.7%)  
Time Between Diagnosis and Genotype     0.07*
<6 months 17 (89.5%) 88 (64.7%)  
6-12 months 0 7 (5.1%)  
>12 months 1 (5.3%) 34 (25.5%)  
Unknown 1 (5.3%) 7 (5.1%)  
  1. * Unknowns removed from analysis.
  2. * “Zerocell adjustments made in calculations.